LISA GALLUCCI: Open Payments
NPI 1548289986 · ROCKVILLE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,885 in 83 payments from 18 companies in 2025. Trend: 2023 $1,820 · 2024 $1,734 · 2025 $1,885
Food & beverage: $1,885
| Company | Payments | Amount |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $324 |
| GENZYME CORPORATION | 9 | $279 |
| Janssen Biotech, Inc. | 7 | $263 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 14 | $231 |
| ABBVIE INC. | 9 | $161 |
| Madrigal Pharmaceuticals | 7 | $145 |
| Ardelyx, Inc. | 3 | $94 |
| Regeneron Healthcare Solutions, Inc. | 3 | $66 |
| QOL Medical, LLC | 2 | $53 |
| Daiichi Sankyo Inc. | 2 | $45 |
Products named: DUPIXENT, TREMFYA, ENTYVIO, XIFAXAN, REZDIFFRA, IBSRELA, RINVOQ, Sucraid.
Industry payments across MD — which companies pay providers there.
